Share this article
Share this article
PROVIDENCE, R.I., Feb. 17, 2021 /PRNewswire/ EpiVax, Inc. ( EpiVax ) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, and better accessibility.
The INDIGO consortium, led by Dr. Remko van Leeuwen (INDIGO s Principal Investigator) of the Amsterdam Institute for Global Health and Development ( AIGHD ), plans to achieve this goal by exploring innovative influenza vaccine concepts. The group will aim to produce novel seasonal (A and B) and avian flu (H7N9 and H5N1) vaccines by combining three cutting-edge elements: novel recombinant HAs with increased immunogenicity, a potent adjuvant, and delivery via needle-free intradermal patches. The consortium will seek to validate this approach by sh
17 febbraio 2021 17:50
Fonte: Adnkronos
#salute-e-benessere
PROVIDENCE, R.I., Feb. 17, 2021 /PRNewswire/ EpiVax, Inc. ( EpiVax ) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, and better accessibility.
The INDIGO consortium, led by Dr. Remko van Leeuwen (INDIGO s Principal Investigator) of the Amsterdam Institute for Global Health and Development ( AIGHD ), plans to achieve this goal by exploring innovative influenza vaccine concepts. The group will aim to produce novel seasonal (A and B) and avian flu (H7N9 and H5N1) vaccines by combining three cutting-edge elements: novel recombinant HAs with increased immunogenicity, a potent adjuvant, and delivery via needle-free intradermal patches. The consortium will seek to valid
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Stellmach) Now is the time for social scientists, funders, global agencies, allied disciplines, and national governments to strategically build core capacities and competencies, and move epidemic social science from the margins to the mainstream. In so doing, social science will challenge the existing status quo. Infectious disease epidemics are increasingly conceived of as events that require socio-political awareness, responses, and solutions. This intensified focus can be seen, for example, in the February 2020 establishment of a COVID-19 Research Roadmap Social Science Working Group by the World Health Organization (WHO). However, various institutional, cultural, and political gaps prevent social science insights on issues such as (mis) trust, (mis/dis) information, the acceptability of laws and mandates, human behaviour and social norms, and stigma and discrimination from being mainstreamed into epidemic response. Based on data collected prior to the COVID-19 pandemic but a
Using economic data to create predictive models of anticipated antimicrobial resistance levels across countries phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.